MDCX

Medicus Pharma Ltd

2.50

Oct 23 • 3:59 PM ET -0.12 (-4.58%)

2.58

Aftermarket • 7:54 PM ET +0.08 (3.20%)

Healthcare Drug Manufacturers - General Canada Nano NASD

Peers: VRCA MBRX PTHS SLGL MIRA IMNN REPL VERU SCYX CPIX

Scroll to Statements

Index	-
Market Cap	4.63M
Enterprise Value	9.21M
Income	-40.99M
Sales	0.00M
Book/sh	-1.03
Cash/sh	5.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Jan 26, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	0.43
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.57
Current Ratio	1.57
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-81.04
EPS next Y	-17.58
EPS next Q	-6.68
EPS this Y	75.87%
EPS next Y	46.80%
EPS next 5Y	51.61%
EPS past 3/5Y	-129.98% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-67.36%
Sales Y/Y TTM	-
EPS Q/Q	51.18%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	-64.71% -

Insider Own	22.91%
Insider Trans	0.00%
Inst Own	22.19%
Inst Trans	-
ROA	-233.02%
ROE	-5705.59%
ROIC	-283.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-51.57%
SMA50	-70.18%
SMA200	-89.86%
Trades

Shs Outstand	1.20M
Shs Float	0.18M
Short Float	40.97%
Short Ratio	0.70
Short Interest	0.07M
52W High	139.00 -98.20%
52W Low	2.55 -1.96%
Volatility	12.85% 11.90%
ATR (14)	0.68
RSI (14)	18.54
Beta	-0.25
Rel Volume	0.80
Avg Volume	105.07K
Volume	84,171

Perf Week	-23.08%
Perf Month	-68.51%
Perf Quarter	-84.29%
Perf Half Y	-84.12%
Perf YTD	-96.73%
Perf Year	-97.94%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	203.75
Prev Close	2.62
Price	2.50
Change %	-4.58%

Oct-08-26 10:41AM	Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing (InvestorsHub) -36.39%
09:04AM	Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances (Proactive)
08:00AM	Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value (GlobeNewswire)
Sep-29-26 08:59AM	Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA (Proactive)
07:30AM	Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer (GlobeNewswire)
09:50AM	Loading…
Sep-21-26 09:50AM	Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients (Proactive)
07:30AM	Medicus Pharma Announces Exclusive Development Focus for SkinJect in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment (GlobeNewswire)
Sep-12-26 10:32AM	Medicus Pharma CEO on SkinJect and Pfizer partnership ICYMI (Proactive)
Sep-10-26 11:58AM	Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy (Proactive) -5.28%
10:38AM	Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study (InvestorsHub)
09:45AM	Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment (Proactive)
07:30AM	Medicus Pharma Publishes Abridged Final Phase 2 SkinJect Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose (GlobeNewswire)
07:14AM	Dow falls as Treasury yields jump to highest level since 2023 (Proactive)
Sep-08-26 10:10AM	Dow slides as oil nears $100, US-Canada trade tensions escalate (Proactive)
10:10AM	Dow closes sharply lower as oil surge fuels inflation fears (Proactive)
09:34AM	Loading…
09:34AM	Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs (Proactive)
08:53AM	Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy (InvestorsHub)
07:30AM	Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company (GlobeNewswire)
Aug-13-26 08:32AM	Medicus Pharma advances pipeline during Q2 with key milestones (Proactive) +6.92%
Aug-12-26 06:00PM	Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-03-26 09:08AM	Medicus Pharma CMO to lead Antev's Teverelix clinical programme (Proactive) +9.37%
07:30AM	Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom (GlobeNewswire)
Aug-01-26 02:00PM	Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI (Proactive)
Jul-31-26 09:24AM	Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix (Proactive)
07:30AM	Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix in Women with Endometriosis (GlobeNewswire)
Jul-27-26 12:07PM	Medicus Pharma cleared by FDA for registrational Phase 2b trial in patients with Gorlin Syndrome (Proactive) -14.00%
09:34AM	Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome (Proactive)
08:28AM	Dow closes higher as oil tumbles, Nasdaq slips with Nvidia leading chip selloff (Proactive)
08:17AM	Medicus Pharma Receives FDA "Study May Proceed" Letter for NDA-Enabling Registrational SkinJect Study in Patients with Gorlin Syndrome (GlobeNewswire)
Jul-18-26 12:24PM	Medicus Pharma CEO details Teverelix progress ICYMI (Proactive)
12:48PM	Loading…
Jul-17-26 12:48PM	Medicus Pharma advances Phase 2 study following FDA and IRB feedback (Proactive) -7.44%
Jul-16-26 08:37AM	Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval (Proactive) +16.53%
07:30AM	Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix Novel Study in Acute Urinary Retention (GlobeNewswire)
Jun-22-26 07:30AM	Medicus Pharma to Showcase SkinJect Registrational Strategy and Teverelix Precision Medicine Program at Bio International 2026 (GlobeNewswire)
Jun-20-26 09:00AM	Medicus Pharma advances Teverelix in prostate cancer - ICYMI (Proactive)
Jun-15-26 08:47AM	Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome (Proactive) -5.24%
07:30AM	Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome (GlobeNewswire)
Jun-11-26 08:50AM	Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE (Proactive)
07:30AM	Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix in Endometriosis utilizing the Emirati Genome Program (GlobeNewswire)
Jun-08-26 08:50AM	Medicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix (Proactive)
07:30AM	Medicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission (GlobeNewswire)
Jun-06-26 11:26AM	Medicus Pharma advances SkinJect for Gorlin syndrome ICYMI (Proactive)
Jun-05-26 11:43AM	Medicus Pharma advances SkinJect toward registrational trial for rare Gorlin Syndrome (Proactive) -6.32%
Jun-03-26 09:09AM	Medicus Pharma advances SkinJect program with FDA submission targeting Gorlin Syndrome (Proactive) +6.97%
08:00AM	Medicus Pharma Advances SkinJect into Registrational Development for Gorlin Syndrome (GlobeNewswire)
May-28-26 09:25AM	Medicus Pharma secures up to $22M in non-dilutive financing facility (Proactive) +6.74%
08:00AM	Medicus Pharma Announces $22 Million Non-Dilutive Financing (GlobeNewswire)
May-15-26 08:28AM	Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress (Proactive) -10.68%
May-14-26 04:30PM	Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +5.28%
May-06-26 12:12PM	Medicus Pharma reports strong Phase 2 dose response in skin cancer study (Proactive) +20.95%
09:27AM	Medicus Pharma highlights positive dose-response in updated skin cancer trial results (Proactive)
08:01AM	Nasdaq and S&P surge to new records on Iran deal hopes, AMD and Disney gains (Proactive)
07:30AM	Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response (GlobeNewswire)
Apr-27-26 09:23AM	Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome (Proactive) -5.68%
07:30AM	Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill (GlobeNewswire)
07:30AM	Dow leads markets lower as investors gear up for mega-cap earnings, Fed meeting (Proactive)
Apr-24-26 04:15PM	Medicus Pharma advances Skinject in rare disease ICYMI (Proactive) -5.18%
Apr-20-26 11:32AM	Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indication (Proactive)
Apr-17-26 09:02AM	Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder (Proactive) +16.98%
08:00AM	Dow rockets higher as Strait of Hormuz stays open, talks eyed (Proactive)
08:00AM	Dow powers higher as oil slump, easing tensions lift stocks (Proactive)
07:30AM	Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect in Gorlin Syndrome (GlobeNewswire)
Apr-16-26 10:30AM	BC-Most Active Stocks (Associated Press)
Apr-15-26 10:30AM	BC-Most Active Stocks (Associated Press) -25.04%
07:30AM	Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression (GlobeNewswire)
07:29AM	Nasdaq pushes ahead but Dow Jones slips, Trump eyes more Iran talk (Proactive)
05:07AM	Medicus Pharma to present new Teverelix data at upcoming endocrinology meeting (Proactive)
Apr-10-26 01:43PM	Medicus Pharma gives Teverelix Phase 2 FDA update ICYMI (Proactive) -6.33%
Apr-06-26 04:15PM	Nasdaq leads Wall Street higher in the face of Iran tensions and oil volatility (Proactive) +9.82% -8.33%
11:26AM	Medicus Pharma submits optimized Phase 2 study design for Teverelix (Proactive)
10:38AM	Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA (Proactive)
07:30AM	Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention (GlobeNewswire)
Apr-04-26 10:00AM	Medicus Pharma SkinJect Phase 2 study data endorsed by independent expert - ICYMI (Proactive)
Apr-01-26 03:43PM	Nasdaq and Dow continue rally as Trump says Iran asks for ceasefire (Proactive) -8.50%
09:48AM	Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data (Proactive)
07:30AM	Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset (GlobeNewswire)
Mar-30-26 04:22PM	Dow Jones alone in the green, Nasdaq slumps as Trump says Iran talks 'serious' (Proactive) -9.64% +12.89%
03:44PM	Dow Jones alone in the green as Trump says Iran talks 'serious' (Proactive)
08:38AM	Medicus Pharma highlights independent support for Phase 2 SkinJect results (Proactive)
07:30AM	Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate (GlobeNewswire)
Mar-26-26 08:36AM	Medicus Pharma advances SkinJect, Teverelix programs, eyes catalyst-rich 2026 (Proactive) -5.71%
07:30AM	Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan (GlobeNewswire)
Mar-25-26 04:30PM	Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-18-26 07:30AM	Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst (ACCESSWIRE)
Mar-16-26 07:30AM	Medicus Pharma Announces SkinJect Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 (GlobeNewswire)
Mar-14-26 09:00AM	Medicus Pharma CEO discusses promising Phase 2 SkinJect results - ICYMI (Proactive)
Mar-10-26 07:30AM	Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum (ACCESSWIRE)
Mar-09-26 11:10AM	Medicus Pharma provides additional Phase 2 data for SkinJect Cancer therapy (Proactive) +34.26%
08:39AM	Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer (Proactive)
07:30AM	Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect Dataset (GlobeNewswire)
Mar-07-26 08:00AM	Medicus Pharma CEO discusses Phase 2 skin cancer results - ICYMI (Proactive)
Mar-05-26 03:49PM	Dow Jones continues to fall as oil prices climb (Proactive) -50.88%
11:41AM	Medicus Pharma reports positive phase 2 results for microneedle skin cancer treatment (Proactive)
09:13AM	Medicus Pharma Stock Swings After Skin Cancer Treatment Results (Benzinga)
08:35AM	Medicus Pharma reports positive Phase 2 results for microneedle treatment for basal cell carcinoma (Proactive)
07:30AM	Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200µg Cohort (GlobeNewswire)
Mar-03-26 07:30AM	Medicus Pharma To Participate in the 38th Annual Roth Conference (GlobeNewswire)
Feb-14-26 11:30AM	Medicus Pharmas Teverelix Phase 2b trial cleared by FDA - ICYMI (Proactive)
Feb-12-26 11:39AM	Medicus Pharma cleared to launch Phase 2b Teverelix study in Prostate Cancer (Proactive)
07:30AM	Medicus Pharma on Bloomberg World (ACCESSWIRE)

Show Previous News

Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops a product, SkinJectTM, with an indication for basal cell carcinoma. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

M.D.Dr. Raza Bokhari M.B.A.

F.A.C.S.Dr. Edward J. Brennan Jr.

Chief Medical OfficerDr. Faisal Mehmud M.D.

Chief Operating OfficerMr. Andrew Alasdair Smith

Senior Vice President of Investor RelationsMs. Anna Baran-Djokovic J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MDCX

Medicus Pharma Ltd

Upgrade your Finviz experience